Program  Highlights

Program  Highlights

The scientific program of ICLE 2023 will present the latest cutting-edge science in the field of lymphocyte engineering and will furthermore discuss how the new research translates for clinical implications.

To get better understanding of what will be the focus next September in Munich browse the topic highlights below.

UPDATE ON THE
APPROVED THERAPIES

First look at post marketing
real world data on the
approved CAR-T cell therapies.

CURRENTLY ONGOING
CLINICAL TRIALS

Discover clinical data
from company, as well as
investigator initiated trials.

NOVEL CLINICAL APPROACHES AND COMBINATION THERAPIES

Potential synergy b/n engineered lymphocytes & other treatment modalities will be demonstrated.

SUPER POWERED
LYMPHOCYTES

Learn more about engineering of lymphocytes for the co-expression of varied immune effectors in addition to the transgenic receptor.

NON-VIRAL
CAR/TCR ENGINEERING

Recent advancement in non viral lymphocyte engineering by means of electroporation or nanocarriers encapsulating mRNA or DNA.

UNIVERSAL DONOR CELLS &
ADVANCED TCR ENGINEERING

A deeper look at
allogeneic therapies,
including those applying
genome editing technologies.

BEYOND
ALPHA-BETA T CELLS

Discuss the engineering of alternative leukocytes including Gamma-Delta T cells, iNKT cells, NK cells, B cells and macrophages.

IN VIVO
T CELL ENGINEERING

Advancement in the scalable engineering of lymphocytes in vivo, reducing costs, timelines and pre conditioning requirements.

TARGETING
NON-MALIGNANT DISEASES

Targeting of non-malignant diseases, including infectious diseases, auto-immune diseases, cardiovascular diseases, genetic disorders and more.